Ozanimod for Pregnant Women with Multiple Sclerosis

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Recruiting Observational Study
Multiple Sclerosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Female
Study type
Observational
Participants needed
1,182 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for pregnant women diagnosed with multiple sclerosis. It aims to gather information on the effects of a medication called ozanimod during pregnancy and how it affects mothers and their babies.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with multiple sclerosis.
  • I am currently or recently pregnant.
  • I live in the United States, Canada, or Germany.

You may not be able to join if

  • I have been exposed to other S1P therapies during the first trimester.
  • I have used cladribine during the first trimester.
  • I have used mitoxantrone during the first trimester.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of Multiple sclerosis (MS) * Currently or recently pregnant * Reside in the United States, Canada or Germany. Exclusion Criteria: • Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester. Other protocol-defined inclusion/exclusion …
Contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain the NCT# and Site #.

CONTACT